Coho Partners Ltd. lowered its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 6.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 335,044 shares of the company's stock after selling 23,800 shares during the quarter. Coho Partners Ltd.'s holdings in Kenvue were worth $7,153,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in KVUE. Grove Bank & Trust raised its holdings in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock valued at $25,000 after acquiring an additional 947 shares during the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of Kenvue during the fourth quarter worth approximately $29,000. Riverview Trust Co acquired a new position in Kenvue in the 3rd quarter valued at $30,000. Fortitude Family Office LLC lifted its holdings in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Ashton Thomas Securities LLC purchased a new position in Kenvue in the 3rd quarter valued at $35,000. Hedge funds and other institutional investors own 97.64% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have recently commented on the stock. Canaccord Genuity Group reduced their target price on shares of Kenvue from $27.00 to $24.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a "buy" rating to a "hold" rating and dropped their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Royal Bank of Canada reissued a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Barclays dropped their price target on Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research report on Friday, January 17th. Finally, UBS Group reduced their price objective on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $23.00.
Check Out Our Latest Analysis on KVUE
Kenvue Trading Up 0.3 %
Shares of Kenvue stock traded up $0.07 during trading hours on Tuesday, hitting $22.00. The company's stock had a trading volume of 14,108,282 shares, compared to its average volume of 13,227,534. The firm has a fifty day moving average of $21.30 and a 200-day moving average of $22.12. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock has a market cap of $42.17 billion, a price-to-earnings ratio of 41.50, a P/E/G ratio of 2.16 and a beta of 1.45. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46.
Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Research analysts forecast that Kenvue Inc. will post 1.05 EPS for the current year.
Kenvue Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.73%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue's payout ratio is 154.72%.
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Articles
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
